Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas, São Paulo, Brazil.
Contraception. 2011 Aug;84(2):122-7. doi: 10.1016/j.contraception.2010.11.007. Epub 2010 Dec 24.
There are many controversies on the association between depot medroxyprogesterone acetate (DMPA) and bone mineral density (BMD). This study reevaluated BMD in postmenopausal women who had used DMPA as a contraceptive until they reached menopause and compared them with non-users. BMD had previously been measured in these women either at 1 year or 2-3 years after menopause and was reassessed in these women 2 years later. Therefore, comparisons were made between the first and third years and between the second to third and fourth to fifth years after menopause.
BMD was reevaluated using dual-energy X-ray absorptiometry at two parts of the non-dominant forearm up to 5 years after menopause in 79 women between 46 and 61 years old: 24 former DMPA users and 55 former copper intrauterine device (IUD) users.
With respect to the former DMPA users, only the BMD measurement at the distal radius in the first year (mean±SEM, 0.425±0.017) was significantly higher than the third-year measurement (0.406±0.017) (p<.015). No significant differences were found at the ultradistal radius. There were no significant differences between the groups of former DMPA and IUD users with respect to BMD measurements either at the distal radius or at the ultradistal radius. There was a direct relationship between higher body mass index (kg/m(2)) and higher BMD at the distal radius between the first and third years. At the ultradistal radius, there was an indirect relationship between older age and lower BMD between the first and third years in both groups.
No statistically significant differences were found in forearm BMD measurements between postmenopausal women who had been long-term users of DMPA and those who had been long-term users of an IUD until menopause. Evaluation of BMD after the menopause showed slightly higher values in former DMPA users compared with non-users.
关于长效醋酸甲羟孕酮(DMPA)和骨密度(BMD)之间的关联存在许多争议。本研究重新评估了使用 DMPA 作为避孕措施直至绝经的绝经后妇女的 BMD,并将其与未使用者进行了比较。这些女性的 BMD 此前已经在绝经后 1 年或 2-3 年后进行了测量,并在 2 年后对这些女性进行了重新评估。因此,对绝经后第 1 年和第 3 年以及第 2 年至第 3 年和第 4 年至第 5 年进行了比较。
在 79 名年龄在 46 至 61 岁之间的绝经后女性中,使用双能 X 射线吸收仪对非优势前臂的两个部位进行 BMD 重新评估:24 名以前使用 DMPA 的女性和 55 名以前使用铜宫内节育器(IUD)的女性。
就前 DMPA 用户而言,只有第 1 年(平均值±SEM,0.425±0.017)远端桡骨的 BMD 测量值明显高于第 3 年(0.406±0.017)(p<.015)。在超远端桡骨处没有发现显著差异。在远端桡骨和超远端桡骨处,前 DMPA 和 IUD 用户的 BMD 测量值之间没有显著差异。第 1 年和第 3 年之间,较高的体重指数(kg/m²)与远端桡骨的较高 BMD 呈直接关系。在超远端桡骨处,第 1 年和第 3 年之间,年龄较大与 BMD 较低呈间接关系,在两组中均如此。
长期使用 DMPA 和长期使用 IUD 直至绝经的绝经后妇女之间,前臂 BMD 测量值没有统计学上的显著差异。绝经后 BMD 的评估显示,与未使用者相比,前 DMPA 使用者的 BMD 值略高。